GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Short Interest

Diamyd Medical AB (FRA:DMN) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Diamyd Medical AB's Short Interest

For the Biotechnology subindustry, Diamyd Medical AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Short Interest falls into.


;
;

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Short Interest
Comparable Companies
OSTO:SANION OSTO:XSPRAY OSTO:EGTX OSTO:HNSA OSTO:SYNACT OSTO:IBT B OSTO:GENO XSAT:HAMLET B OSTO:VICO OSTO:FLUO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
DYMDF:USA DMYD B:Sweden
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines